Clinical trial
SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or…
NCT00006384 · City of Hope Medical Center, Other · Completed
Key facts
| NCT number | NCT00006384 |
|---|---|
| Title | SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer |
| Official title | Phase II Trial of SU5416 and Interferon Alfa 2B in Unresectable or Metastatic Renal Cell Carcinoma |
| Lead sponsor | City of Hope Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa, semaxanib |
| Start date | Nov 1, 2000 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Dec 24, 2003 |
| Last update posted | Oct 20, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: